ArcherDX Launches VariantPlex™ p53 Panel for Targeted NGS
ArcherDX expands the application of its Anchored Multiplex PCR (AMP™) technology to include DNA variant detection with the Archer™ VariantPlex™ p53 Panel. The panel is a targeted next-generation sequencing (NGS)-based assay to detect germline and somatic mutations of the TP53 gene, which is frequently mutated in cancer. “With complete exon coverage of TP53, a simple, lyophilized workflow and advanced mutation analysis software, the p53 assay is the first sequencing solution to analyze p53 mutations using AMP enrichment chemistry,” said Jason Myers, CEO and co-founder of ArcherDX.
“With >99% on-target coverage and the ability to detect both known and de novo mutations, this assay is an ideal tool to determine mutated or wild-type p53 status.”
The Archer VariantPlex p53 assay was designed to provide a full exonic sequence of the TP53 gene. “The p53 mutation status, specifically wild-type versus mutated, is used as either inclusion or exclusion criteria for targeting apoptosis and cell cycle regulators such as MDM2 and Wee1,” said Jill Stefanelli, Director of Pharma Business Development at ArcherDX. Todd Pollard, VP of Global Sales and Support, elaborated, “With >99% on-target coverage and the ability to detect both known andde novo mutations, this assay is an ideal tool to determine mutated or wild-type p53 status.”
About the VariantPlex NGS Assays
Archer VariantPlex assays utilize AMP enrichment chemistry to capture and amplify sections of the genome frequently mutated in cancers. Single-primer flexibility and molecular barcoding enable quantitative analysis, de-duplication and error correction viaArcher Analysis software, resulting in confident mutation calling. VariantPlex assays can accurately detect single nucleotide variants (SNVs), insertion/deletions (indels) and copy number variations (CNV) from low-input FFPE samples.
VariantPlex assays are part of Archer’s targeted NGS mutation detection workflow that includes library preparation, analysis and reporting. Archer assays use a simple lyophilized workflow optimized to minimize hands-on time and contamination risk during library preparation, making them ideal for high-volume laboratories. The AMP-enabled Archer FusionPlex™ and VariantPlex panels are target enrichment assays used to create libraries for Illumina® or Ion Torrent™ sequencing from small amounts (10-200ng) of nucleic acid extracted from formalin-fixed, paraffin-embedded (FFPE) clinical samples. Once sequenced, the Archer Analysis software provides comprehensive analysis with embedded QC metrics and read visualization to accurately detect and identify known and novel fusions, SNVs, indels and CNVs.
ArcherDX addresses the bottlenecks associated with using NGS in translational research by offering a robust platform for targeted sequencing applications.
By combining proprietary Anchored Multiplexed PCR (AMP™) chemistry and easy-to-use, lyophilized reagents, Archer NGS assays generate highly enriched sequencing libraries to detect gene fusions, SNVs, indels and CNVs. Complemented by the Archer suite of bioinformatics software, ArcherDX technology dramatically enhances complex mutation identification and discovery.
ArcherDX is headquartered in Boulder, Colo., and maintains manufacturing operations in Beverly, Mass. www.archerdx.com
Note: Archer kits and analysis software are for research use only and not for use in diagnostic procedures.
Jason Amsbaugh, +1 303-357-9001